Lipid Modifiers and NASH: Statins, Ezetimibe, Fibrates, and Other Agents

Non-Alcoholic Fatty Liver Disease: A Practical Guide

Volumn , Issue , 2013, Pages 293-307

  Musso, Giovanni ^a   Molinaro, Federica ^b   Paschetta, Elena ^b   Gambino, Roberto ^b   Cassader, Maurizio ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cholesterol lowering drugs; Ezetimibe; Hyperlipidemia; Lipid lowering drugs; Non alcoholic fatty liver disease (NAFLD); Polyunsaturated fatty acid (PUFA); Statins

Indexed keywords

EID: 84886142392     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118556153.ch26     Document Type: Chapter

References (50)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55: 2005-23.
2. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43: 617-49.
3. Musso G, Gambino R, De Michieli F, et al. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med. 2008;40:383-94.
4. Musso G, Cassader M, Michieli F, et al. Adipose tissue dysfunction predicts liver histology, glucose and lipid metabolism in NAFLD: role of maladaptive adipocyte response to fat ingestion. Hepatology. 2012 Jun 8. doi:10.1002/hep.25739.
5. Marí M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab. 2006;4:185-98.
6. Wouters K, van Bilsen M, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Letters. 2010;584: 1001-5.
7. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes non-alcoholic steatohepatitis. Gastroenterology. 2011. doi:10.1053/j.gastro.2011.06.040.
8. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665-74.
9. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with nonalcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol. 2009;44:471-7.
10. Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J Gastroenterol. 2010;16:800-3.
11. Puri P, Wiest MM, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-90.
12. Caballero F, Fernández A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatology 2009;50:789-96.
13. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990-4.
14. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376: 1916-22.
15. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71-7.
16. Pramfalk C, Parini P, Gustafsson U, et al. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011;269:333-9.
17. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol. 2012;24:164-71.
18. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res. 2010;40:613-21.
19. Park H, Shima T, Yamaguchi K, et al. Efficacy of longterm ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101-7.
20. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers and apolipoprotein B-100 kinetics in insulinresistant obese subjects on a weight loss diet. Diabetes Care. 2010;33:1134-9.
21. Takeshita Y, Takamura T, Kita Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: a randomized controlled trial. J Hep. 2011;54:S346.
22. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C-81C.
23. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42.
24. Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166-71.
25. Arase Y, Suzuki F, Kobayashi M, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med. 2011;50:1081-7.
26. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21:406-12.
27. Suzuki T, Toyohara T, Akiyama Y, et al. Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci. 2011;100: 3696-707.
28. Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol. 2011;7:385-97.
29. Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes. 2010;1:116-28.
30. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
31. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305:1659-68.
32. Vilà L, Rebollo A, Ad{stroke}alsteisson GS, et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol. 2011;251:32-40.
33. Kobayashi M, Gouda K, Chisaki I, et al. Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011;662(1-3):9-14.
34. Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced nonalcoholic fatty liver disease in mice. Eur J Pharmacol. 2008;584: 118-24.
35. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol. 2009;51:548-56.
36. Park H, Hasegawa G, Shima T, et al. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Clin Chim Acta. 2010;411:21-2.
37. Abel T, Fehér J, Dinya E, et al. Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease. Orv Hetil. 2009;150:989-93.
38. Nozaki Y, Fujita K, Yoneda M, http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wada%20K%22%5B Author%5D et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol. 2009;51:548-56.
39. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010;12: 224-33.
40. Nagai K, Matsumaru K, Takahashi Y, Nakamura N. Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities. Case Rep Gastroenterol. 2011;5:336-43.
41. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003;38: 1529-39.
42. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferatoractivated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol. 2006;169:846-60.
43. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and metaanalysis of randomised trials. Diabetologia. 2012;55: 885-904.
44. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350-3.
45. Caldwell SH, Argo CK, Henry TD, et al. Dissociated histological and metabolic effects of omega-3 (3000 mg/d) vs. placebo with both exercise and diet in a double-blind randomized controlled trial of NASH. J Hep. 2011;54:S8.
46. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatology. 2003;38:414-8.
47. Seo YS, Kim JH, Jo NY, et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol. 2008;23:102-9.
48. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384.
49. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:2727-35.
50. Musso G, Gambino R, Cassader M. Need for a threefocused approach to nonalcoholic fatty liver disease. Hepatology. 2011;53:1773.